Building Your Care Team: Hiring the Right Experts
At a Glance
Managing scleroderma requires a multidisciplinary medical team led by a specialized rheumatologist or dermatologist. Essential team members include a pulmonologist, cardiologist, gastroenterologist, and dentist. Seek care at a Scleroderma Center of Excellence for the best outcomes.
Because scleroderma is a complex, rare, and multi-system disease, it cannot be managed by a single doctor. You are essentially “hiring” a specialized medical team. To get the best outcomes, you need a team that communicates with each other, led by a “quarterback” who specializes in Systemic Sclerosis (SSc) or a Dermatologist for Morphea [1][2].
Your Multidisciplinary Care Team
A “complete” care team for scleroderma usually includes the following specialists [3][4][2]:
- The Rheumatologist (The Quarterback): For systemic disease, this is your primary specialist. They should perform your Modified Rodnan Skin Score (mRSS) at every visit and coordinate with all other doctors [5][6].
- The Dermatologist: Often the primary diagnosing and managing physician for Localized Scleroderma (Morphea). They coordinate treatments like UVA-1 phototherapy and topical management [7][8].
- The Pulmonologist: Essential for managing Interstitial Lung Disease (ILD) and Pulmonary Arterial Hypertension (PAH), the two leading causes of serious complications [9][10].
- The Cardiologist: Responsible for monitoring heart strain and high blood pressure in the lungs using specialized tools like the DETECT algorithm and echocardiograms [11][12].
- The Gastroenterologist: Since GI issues (like reflux or bloating) affect nearly all patients, a GI specialist familiar with scleroderma-related motility issues is vital [3][13].
- The Dentist: Scleroderma can cause microstomia (a smaller mouth opening) and dry mouth, which increases the risk of tooth decay. A dentist familiar with these challenges is a key part of your team [5][14].
Vetting Your Specialist
Not all rheumatologists are experts in scleroderma. Because the disease is so rare, many local doctors may only see a few cases a year [2]. When “interviewing” a new doctor, look for these signs of expertise:
- Standardized Testing: They should use the mRSS (a 17-point skin pinch test) to objectively track your disease [5][6].
- Subtype Classification: They should be able to clearly tell you if you have limited (lcSSc) or diffuse (dcSSc) cutaneous disease, as this determines your screening schedule [3][10].
- Center Affiliation: Expertise is often higher at a Scleroderma Center of Excellence, where doctors see hundreds of cases and participate in the latest clinical trials [15][16].
Preparing for Your First Visit
To make the most of your first consultation, you should bring physical copies (not just “the doctor has them”) of the following [17][18]:
- Full Antibody Panel: Ensure you have the results for Anti-Scl-70 (ATA), Anticentromere (ACA), and Anti-RNA Polymerase III [19][20].
- Imaging Reports and Disks: Bring the actual reports for your High-Resolution CT (HRCT) scan of the lungs and your Echocardiogram [10][18].
- Pulmonary Function Tests (PFTs): Bring the full printout showing your FVC and DLCO numbers [18].
- Nailfold Capillaroscopy Reports: If this microscopic exam of your cuticles has been done, the images or report are essential for staging your disease [21][17].
Having these records ready allows the specialist to spend their time examining you and creating a treatment plan, rather than hunting for old paperwork [18].
Common questions in this guide
What kind of doctor is the main specialist for systemic sclerosis?
Which specialists should be on my scleroderma care team?
What medical records should I bring to my first scleroderma appointment?
What is a Scleroderma Center of Excellence?
Related questions
Get notified when new evidence is published on Scleroderma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (21)
- 1
Management of pregnancy with diffuse cutaneous systemic sclerosis: a case report and literature review.
Yang L, Sun W, Yao Q
The Journal of international medical research 2021; (49(11)):3000605211060160 doi:10.1177/03000605211060160.
PMID: 34851779 - 2
Caring for the Patient With Limited Systemic Scleroderma.
Lachner KD
Orthopedic nursing 2016; (35(1)):5-10; quiz 11-2 doi:10.1097/NOR.0000000000000212.
PMID: 26814000 - 3
Comprehensive description of the prevalence, serological and clinical characteristics, and visceral involvement of systemic sclerosis (scleroderma) in a large cohort from the United Arab Emirates Systemic Sclerosis Registry.
Namas R, Elarabi M, Khan S, et al.
Journal of scleroderma and related disorders 2023; (8(2)):137-150 doi:10.1177/23971983221145788.
PMID: 37287950 - 4
Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.
Lescoat A, Roofeh D, Kuwana M, et al.
Clinical reviews in allergy & immunology 2023; (64(3)):239-261 doi:10.1007/s12016-021-08891-0.
PMID: 34468946 - 5
Cutaneous Features, Autoantibody Profile, and Nailfold Capillaroscopy of Systemic Sclerosis: A Study of 60 Cases.
Dave J, Mahajan S, Khadilkar P, Pradhan V
The Journal of the Association of Physicians of India 2022; (70(11)):11-12 doi:10.5005/japi-11001-0136.
PMID: 37355940 - 6
Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
Khanna D, Clements PJ, Volkmann ER, et al.
Arthritis research & therapy 2019; (21(1)):23 doi:10.1186/s13075-019-1809-y.
PMID: 30651141 - 7
Effectiveness of PUVA vs. UVA1 phototherapy in the treatment of morphea patients.
Malewska-Woźniak A, Osmola-Mañkowska A, Adamski Z
Postepy dermatologii i alergologii 2022; (39(4)):757-761 doi:10.5114/ada.2021.108437.
PMID: 36090739 - 8
Morphea and Eosinophilic Fasciitis: An Update.
Mertens JS, Seyger MMB, Thurlings RM, et al.
American journal of clinical dermatology 2017; (18(4)):491-512 doi:10.1007/s40257-017-0269-x.
PMID: 28303481 - 9
Clinical features and prognostic factors of systemic sclerosis in Guangxi, China: Retrospective, single-center study of long-term survival in 470 patients.
Chen J, Yang C, Pan J, et al.
International journal of rheumatic diseases 2022; (25(2)):182-191 doi:10.1111/1756-185X.14261.
PMID: 34889515 - 10
Systemic Sclerosis and Pulmonary Disease.
Ngo K
Advances in experimental medicine and biology 2021; (1303()):173-182 doi:10.1007/978-3-030-63046-1_10.
PMID: 33788193 - 11
B-type Natriuretic Peptide as a Marker of Different Forms of Systemic Sclerosis.
Nešković JS, Ristić A, Petronijević M, et al.
Journal of medical biochemistry 2018; (37(4)):406-414 doi:10.1515/jomb-2017-0058.
PMID: 30584399 - 12
Pulmonary hypertension in connective tissue diseases: an update.
Aithala R, Alex AG, Danda D
International journal of rheumatic diseases 2017; (20(1)):5-24 doi:10.1111/1756-185X.13001.
PMID: 28205373 - 13
Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment.
Sundblad V, Gomez RA, Stupirski JC, et al.
Frontiers in pharmacology 2021; (12()):650605 doi:10.3389/fphar.2021.650605.
PMID: 33959016 - 14
Assessment of Central Corneal Thickness in Different Subtypes of Systemic Sclerosis.
Gomes BA, Santhiago MR, Kara-Junior N, et al.
Ocular immunology and inflammation 2016; (24(6)):693-698 doi:10.3109/09273948.2015.1076008.
PMID: 26652214 - 15
New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
Lescoat A, Varga J, Matucci-Cerinic M, Khanna D
Expert opinion on investigational drugs 2021; (30(6)):635-652 doi:10.1080/13543784.2021.1923693.
PMID: 33909517 - 16
Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry.
Shanmugam VK, Frech TM, Steen VD, et al.
Clinical rheumatology 2020; (39(1)):93-102 doi:10.1007/s10067-019-04792-y.
PMID: 31667644 - 17
Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma.
Chong WH, Saha BK, Beegle S
The American journal of the medical sciences 2023; (365(2)):198-204 doi:10.1016/j.amjms.2022.01.023.
PMID: 35276077 - 18
Sarcopenia in systemic sclerosis: the impact of nutritional, clinical, and laboratory features.
Corallo C, Fioravanti A, Tenti S, et al.
Rheumatology international 2019; (39(10)):1767-1775 doi:10.1007/s00296-019-04401-w.
PMID: 31372720 - 19
Serodiscordant patients with systemic sclerosis: when antibody does not correspond to skin involvement.
Iniesta Arandia N, Espinosa G, Tolosa Vilella C, et al.
Clinical and experimental rheumatology 2020; (38 Suppl 125(3)):106-114.
PMID: 31969223 - 20
Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis.
Tartar DM, Chung L, Fiorentino DF
Clinics in dermatology 2018; (36(4)):508-524 doi:10.1016/j.clindermatol.2018.04.008.
PMID: 30047434 - 21
Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis.
Maciejewska M, Stec A, Zaremba M, et al.
Clinical, cosmetic and investigational dermatology 2023; (16()):1351-1361 doi:10.2147/CCID.S409490.
PMID: 37255624
This guide on building a scleroderma care team is for educational purposes only. Always consult your rheumatologist or primary care physician for personalized medical advice and treatment coordination.